Health Care & Life Sciences » Biotechnology | Anthera Pharmaceuticals Inc.

Anthera Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
-
3,185.00
145.00
-
Cost of Goods Sold (COGS) incl. D&A
353.00
344.00
-
-
281.00
Gross Income
353.00
344.00
-
-
281.00
SG&A Expense
27,894.00
28,115.00
40,781.00
57,317.00
36,251.00
EBIT
28,247.00
28,459.00
37,881.00
-
36,532.00
Unusual Expense
-
-
-
1,744.00
9,643.00
Non Operating Income/Expense
15.00
96.00
2,661.00
171.00
15.00
Interest Expense
2,599.00
1,049.00
-
-
-
Pretax Income
30,861.00
29,604.00
35,220.00
55,523.00
26,874.00
Consolidated Net Income
30,861.00
29,604.00
35,220.00
55,523.00
26,874.00
Net Income
30,861.00
29,604.00
35,220.00
55,523.00
26,874.00
Net Income After Extraordinaries
30,861.00
29,604.00
35,220.00
55,523.00
26,874.00
Net Income Available to Common
30,861.00
29,604.00
35,220.00
66,437.00
29,377.00
EPS (Basic)
13.52
10.88
7.92
102.96
2.86
Basic Shares Outstanding
2,283.40
2,722.00
4,453.90
645.50
10,278.40
EPS (Diluted)
13.52
10.88
7.91
102.93
2.86
Diluted Shares Outstanding
2,283.40
2,722.00
4,453.90
645.50
10,278.40
EBITDA
27,894.00
28,115.00
37,596.00
57,172.00
36,251.00
Preferred Dividends
-
-
-
10,914.00
2,503.00

About Anthera Pharmaceuticals

View Profile
Address
25801 Industrial Boulevard
Hayward California 94545
United States
Employees -
Website http://www.anthera.com
Updated 07/08/2019
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases. It offers Sollpura and blisibimod to treat diseases such as exocrine pancreatic insufficiency and Immunoglobulin A nephropathy. The company was founded by Paul F.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.